<DOC>
	<DOC>NCT00852176</DOC>
	<brief_summary>The study will evaluate the long-term safety and efficacy of intravascular beta radiation therapy to treat coronary in-stent restenosis using the Beta-Cath(TM) 3.5F System; data will be collected retrospectively on patients treated with the Beta-Cath™ 3.5F System in routine clinical practice following FDA pre-market approval of the System. Outcomes will be reported up to 5 years following treatment.</brief_summary>
	<brief_title>Retrospective Long-term Safety and Efficacy Study of the Beta-Cath(TM) 3.5F System</brief_title>
	<detailed_description />
	<criteria>Patients who underwent onlabel treatment (as defined below) with the BetaCath™ 3.5F System (30, 40 or 60mm) for instent restenosis (ISR) after coronary stenting. 1. Onlabel treatment for the 30 and 40mm BetaCath™ 3.5F System is defined as: treatment of ISR in native coronary arteries with discrete lesions (treatable with a 20mm balloon) in reference vessel diameters (RVD) ranging from 2.7mm to 4.0mm 2. Onlabel treatment for the 60mm BetaCath™ 3.5F System is defined as: treatment of ISR in native coronary arteries with lesions &lt;40mm in length in RVD ranging from 2.7mm to 4.0mm Patients must have undergone brachytherapy treatment at least 68 months prior to enrollment in this retrospective study and the date of their treatment must be: 1. On or after February 8, 2002 for the 30/40mm 3.5F System 2. On or after June 25, 2003 for the 60mm 3.5F System Patients who do not give informed consent Patients who do not meet the inclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Coronary brachytherapy</keyword>
	<keyword>Coronary restenosis</keyword>
	<keyword>Coronary in stent restenosis</keyword>
</DOC>